Advisor Partners LLC lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 9.0% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 8,148 shares of the medical research company’s stock after purchasing an additional 670 shares during the period. Advisor Partners LLC’s holdings in Thermo Fisher Scientific were worth $1,422,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the company. Sharkey Howes & Javer lifted its stake in shares of Thermo Fisher Scientific by 1.0% during the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock valued at $113,000 after acquiring an additional 7 shares during the period. Beacon Trust Co. lifted its stake in shares of Thermo Fisher Scientific by 0.6% during the first quarter. Beacon Trust Co. now owns 2,159 shares of the medical research company’s stock valued at $341,000 after acquiring an additional 12 shares during the period. Dumont & Blake Investment Advisors LLC lifted its stake in shares of Thermo Fisher Scientific by 0.3% during the first quarter. Dumont & Blake Investment Advisors LLC now owns 5,526 shares of the medical research company’s stock valued at $849,000 after acquiring an additional 15 shares during the period. Reinhart Partners Inc. lifted its stake in shares of Thermo Fisher Scientific by 0.6% during the second quarter. Reinhart Partners Inc. now owns 3,430 shares of the medical research company’s stock valued at $598,000 after acquiring an additional 20 shares during the period. Finally, Azimuth Capital Management LLC lifted its stake in shares of Thermo Fisher Scientific by 0.8% during the first quarter. Azimuth Capital Management LLC now owns 3,210 shares of the medical research company’s stock valued at $493,000 after acquiring an additional 25 shares during the period. Institutional investors own 83.52% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/09/17/thermo-fisher-scientific-inc-tmo-shares-bought-by-advisor-partners-llc.html.

In other news, VP Seth H. Hoogasian sold 4,140 shares of the business’s stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $177.80, for a total value of $736,092.00. Following the transaction, the vice president now directly owns 25,518 shares of the company’s stock, valued at approximately $4,537,100.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Peter E. Hornstra sold 3,894 shares of the business’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $185.18, for a total value of $721,090.92. Following the completion of the transaction, the vice president now directly owns 19,751 shares in the company, valued at $3,657,490.18. The disclosure for this sale can be found here. Insiders sold a total of 22,738 shares of company stock worth $4,021,512 in the last quarter. Corporate insiders own 0.49% of the company’s stock.

Shares of Thermo Fisher Scientific Inc. (TMO) opened at 190.63 on Friday. The stock’s 50 day moving average price is $180.21 and its 200-day moving average price is $170.53. Thermo Fisher Scientific Inc. has a 52-week low of $139.07 and a 52-week high of $194.30. The firm has a market cap of $74.37 billion, a price-to-earnings ratio of 33.21 and a beta of 1.05.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, beating analysts’ consensus estimates of $2.27 by $0.03. Thermo Fisher Scientific had a return on equity of 11.11% and a net margin of 12.27%. The firm had revenue of $5 billion for the quarter, compared to analyst estimates of $4.92 billion. During the same quarter in the previous year, the company posted $2.03 EPS. The business’s revenue was up 10.2% on a year-over-year basis. On average, analysts forecast that Thermo Fisher Scientific Inc. will post $9.35 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be given a $0.15 dividend. The ex-dividend date is Thursday, September 14th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.31%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.45%.

Several equities analysts have recently issued reports on the company. Zacks Investment Research lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Tuesday, September 12th. Cowen and Company reaffirmed an “outperform” rating and set a $220.00 price target (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Sunday, September 10th. Morgan Stanley reaffirmed an “overweight” rating and set a $220.00 price target on shares of Thermo Fisher Scientific in a research note on Wednesday, September 6th. Bank of America Corporation reaffirmed a “buy” rating and set a $210.00 price target (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Friday, July 21st. Finally, Barclays PLC reaffirmed an “overweight” rating and set a $200.00 price target (up previously from $190.00) on shares of Thermo Fisher Scientific in a research note on Monday, July 17th. One equities research analyst has rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $193.56.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc. and related companies with MarketBeat.com's FREE daily email newsletter.